A director made their first-ever open market purchase of Intellia Therapeutics (NTLA) for $1 million, signaling strong conviction after a recent price drop. This same director's only other purchase was timing the 2019 bottom in AbbVie (ABBV), which has since returned over 275%. On the bearish side, insiders at A&I Pharmaceuticals sold over $35 million worth of stock in a single month after a significant run-up. This record-breaking selling volume from twelve different insiders suggests a shared belief that the stock may be overvalued. Similarly, a key insider at SKYE Bioscience (SKYE) sold a large position, whose only prior sale preceded a 40% drop in the stock.

Infinity Natural Resources

• A director made an unscheduled purchase of nearly $700,000 worth of stock on August 25th.
• This is the director's largest purchase ever out of six previous buys.
• The purchase increased the director's holdings by over 4x, showing significant conviction.
• The stock is currently down nearly 30% in the last six months, suggesting the director sees this as a buying opportunity.
• Past Performance: This director's previous purchases have averaged 20% returns within three months.

Takeaways

• This is a strong bullish signal. An insider making their largest-ever purchase to quadruple their holdings after a significant price drop indicates a strong belief that the stock is undervalued.
• The director's successful track record on previous purchases adds weight to this signal, suggesting they have a good sense of timing for the company's stock.

Texas Pacific Land Corporation (TPL)

• A director made an unscheduled purchase of over $88,000 worth of stock.
• The stock has fallen significantly, down over 30% in the last three months.
• Past Performance: This director has a perfect track record. The stock has gone up after every single one of their previous purchases, which have averaged over 25% returns in a three-month period.

Takeaways

• This is a bullish signal. While the purchase size is relatively small, the director's perfect buying history is a powerful indicator.
• This insider appears to be "buying the dip" in a stock they have timed successfully in the past, suggesting they believe a rebound is likely.

Intellia Therapeutics (NTLA)

• A director purchased $1 million worth of stock.
• This purchase comes after the stock has fallen over 20% in the last month.
• This is the director's first time ever buying NTLA stock on the open market.
• Past Performance: This director's only other open market purchase was of AbbVie (ABBV) in 2019, where they perfectly timed the market low. ABBV stock is up over 275% since that purchase.

Takeaways

• This is a very strong bullish signal. A $1 million purchase is substantial, and the fact that it's a first-time buy indicates new-found conviction from the insider.
• The director's previous home-run trade in ABBV suggests they may be skilled at identifying major buying opportunities in beaten-down stocks. This is a high-conviction signal.

SKYE Bioscience (SKYE)

• A 10% owner of the company made an unscheduled sale of $800,000 worth of stock.
• The sale comes after the stock has risen nearly 60% in the last three months. This is an example of an insider "selling the rip."
• Past Performance: The only other time this insider sold stock, it fell over 40% in the following three months.

Takeaways

• This is a strong bearish signal. An insider is taking a significant profit after a strong run-up in price.
• The insider's previous sale being followed by a major price drop is a critical red flag, suggesting their sales may precede periods of poor stock performance.

Satellogic (SATL)

• The company's President made an unscheduled sale of $100,000 worth of stock.
• This is the President's largest sale ever out of three total sales.
• The stock has had a massive run, up over 240% in the last year, and the President is selling into this strength.
• Past Performance: After the President's two previous sales, the stock fell an average of over 17% in the following three months.

Takeaways

• This is a bearish signal. The President is cashing out with their largest sale ever after a monumental rise in the stock price.
• The pattern of the stock falling after their previous sales suggests this insider may be selling near what they perceive to be a peak.

A&I Pharmaceuticals

• The Head of R&D made a $9 million unscheduled sale.
• This sale follows a significant run-up, with the stock gaining over 50% in the last three months.
• This is part of a much larger trend of insider selling at the company.
  • This was the 12th insider sale in August alone.
  • Total insider sales for the month exceeded $35 million.
  • This is by far the most selling the company has ever seen in a single month.

Takeaways

• This is a very strong bearish signal. The sheer volume of selling from multiple insiders, including a key executive like the Head of R&D, is a major warning sign.
• When a large group of insiders all decide to sell in record numbers after a stock has run up, it strongly implies a shared belief that the stock is overvalued and may be due for a correction.